#quercetin

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

Prvi ljudi koji su uzeli dasatinib i kvercetin: šta je pilot‑studija na 14 pacijenata s IPF pokazala (i nije pokazala)

BY DR. SYNAPSE · 15. окт 2026.

U 2019. godini istraživači su prvi put izveštavali o upotrebi senolitičke kombinacije dasatiniba i kvercetina kod 14 pacijenata sa idiopatskom plućnom fibrozom (IPF). Nakon tri nedelje povremenog doziranja, učesnici su zabeležili značajno veće razdaljine u testu od šest minuta, brže hodanje i brže ustajanje sa stolice, iako se funkcija pluća nije promenila. Pilot‑studija je zabeležila i jedan ozbiljan neželjeni događaj, kao i česte respiratorne, kožne i gastrointestinalne tegobe. Važno je napomenuti da je ovo bila otvorena, nekontrolisana studija lekova za lečenje raka u kombinaciji sa farmakološkim dozama flavonoida, a ne suplementacioni protokol.